Complexed with its intracellular receptor, FKBP12, the natural product rapamycin inhibits G, 
By inhibiting intermediate steps in signal transduction leading
to G, progression of the cell cycle in a variety of mammalian cell lines (1) (2) (3) (4) and in the yeast Saccharomyces cerevisiae (5) (6) (7) , rapamycin may illuminate the events that link mitogenic signaling and the cell cycle machinery. Association with an intracellular FK506-and rapamycin-binding protein (FKBP12) is necessary for the actions of rapamycin (1, 2, 5-7), which has been shown to block the activation of p70 S6 kinase (p7OS6K) (4, (8) (9) (10) and cyclin-dependent kinases (11) (12) (13) (14) . These downstream proteins, however, have been shown not to be the direct target of the FKBP12-rapamycin complex. Recently, a mammalian protein that directly associates with FKBP12-rapamycin was isolated and its encoding gene was cloned independently from human and rat by two research groups (15, 16) . The human protein is designated FRAP (EKBP12-rapamycin-associated protein) (15) , and the rat protein, RAFT1 (rapamycin and FKBP12 target 1) (16) , has >98% sequence identity to FRAP. Human FRAP is a 289-kDa protein composed of 2549 aa. It is highly related to two gene products from S. cerevisiae, TOR1/DRR1 and TOR2/DRR2 (7, (17) (18) (19) , identified through rapamycin-resistant mutations. FRAP is 43% identical to TOR1/DRR1 and 45% identical to TOR2/DRR2. The C-terminal 660 aa of FRAP display a
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greater homology to TOR1/DRR1 (57% identity) and TOR2/ DRR2 (59% identity), which also have homology to several known phosphatidylinositol (PI) kinases, including mammalian PI 3-kinase (20) and a yeast PI 3-kinase, VPS34 (21) . These similarities imply that this C-terminal portion of FRAP may contain a lipid kinase (LK) domain. A potential site for phosphorylation by protein kinase C (PKC) is present in TOR1 (Ser1972-Arg) and TOR2 (Ser1975-Arg), and mutations at Ser'972 [Ser1972 --Arg (S1972R) and S1972N] in TOR1 or at Ser1975 (S1975I) in TOR2 render yeast cells resistant to rapamycin (17, 19) . This Ser-Arg site is conserved in FRAP, which gives rise to the possibility of its involvement in the interaction between FRAP and FKBP12-rapamycin.
Here we report mapping of the minimal human FKBP12-rapamycin-binding domain (FRB domain) in FRAP through a proteolysis approach and utilizing an in vitro transcription/ translation assay system. A small, 90-aa fragment of FRAP is shown to be sufficient to confer specific FKBP12 binding in a rapamycin-dependent fashion, with undiminished binding affinity compared with larger fragments. Further, we have probed the role of Ser2035 in the FKBP12-rapamycin-FRAP binding interactions; this residue is most probably located in the interface between FRAP and FKBP12-rapamycin, and replacement with any residue that contains a larger side chain, including mimics of phosphoserine, abolishes binding activity, presumably due to steric hindrance or an induced conformational change.
MATERIALS AND METHODS
Plasmids, Bacteria, and DNA Manipulations. The vector pGEX-2T (Pharmacia) was used for expression of glutathione S-transferase (GST) fusion proteins in Escherichia coli strain BL21. In vitro transcription/translation was carried out on the vector pET-5a, which contains a phage T7 promoter (22) . Site-specific mutagenesis was performed according to Kunkel (23) 
RESULTS
C Terminus of FRAP Contains the FRB Domain. Partial purification of bovine brain FRAP by use of GFK rapamycin and glutathione affinity chromatography has been reported (15) . Using the same strategy combined with tryptic digestion of crude proteins before addition of GFK-rapamycin, we were able to identify a spectrum of proteolytic fragments of FRAP with FKBP12-rapamycin binding affinity. In addition to fulllength FRAP, which ran as a 220-kDa band in an SDS/7.5% polyacrylamide gel, protein bands of approximately 200, 140, 120, 75, and 40 kDa appeared after tryptic digestion (Fig. 1A) . These proteins were retained on glutathione-Sepharose after incubation with GFK-rapamycin, but not with GFK-FK506. After electroblotting of the proteins to a poly(vinylidene difluoride) membrane, the 75-kDa fragment was isolated and subjected to N-terminal microsequencing, the result of which aligned the N terminus of this fragment with aa 1819 of human FRAP (Fig. 1B) . The high degree of sequence identity between bovine and human FRAP has been shown previously (15) . Therefore, the 75-kDa fragment that contains the FRB domain is composed of the last 730 aa of FRAP. Sequence alignment of FRAP and its yeast homolog TOR1 (19) (Fig. 2) . The C-terminal fragment, the presumed LK domain, did not bind FKBP12 or either of the FKBP12-drug complexes. It abrogates binding of the TOR1 protein to FKBP12-rapamycin (X.-F.Z., unpublished work). This serine is conserved in FRAP (residue 2035), suggesting its possible involvement in the interaction with FKBP12-rapamycin. Indeed, S2035R mutation in the 46-kDa fragment abolished its affinity for FKBP12-rapamycin (Fig. 2) . Having identified this crucial residue for binding, we systematically truncated the 46-kDa fragment and carried out binding assays using fragments encompassing this serine (Fig. 3) . The smallest fragment that binds FKBP12-rapamycin spanned aa 2025-2114, with a calculated molecular mass of 11 kDa. Further deletion of this fragment either from the N terminus (10 aa) or the C terminus (25 aa) abrogated binding activity completely. To determine whether or not this minimal FRB domain has similar affinity for its target when compared with larger fragments, we estimated the dissociation constants of the 46-kDa (aa 1819-2206), 20-kDa (aa 1995-2174), and 11-kDa fragments for binding to FKBP12-rapamycin. The binding curves were generated from binding assays as described above with subnanomolar concentrations of labeled FRAP fragments and various concentrations of GFK-rapamycin (1:1) (Fig. 4 ; autoradiographs of SDS/polyacrylamide gels are shown as insets). The three fragments displayed very similar FKBP12-rapamycin binding affinity, with equilibrium dissociation constants around 5 nM (Fig. 3) . Therefore, the minimal FRB domain has undiminished affinity for its target compared with larger fragments. Although it is possible that these affinities are overestimated due to the nature of our assay method, they should at least be useful in a comparative context (19) . To probe the possible involvement of a phosphoserine at this site in the interaction between FRAP and FKBP12-rapamycin, we introduced several mutations and examined the mutants' ability to bind FKBP12-rapamycin. A 20-kDa fragment (aa 1995-2174) was used for the mutation studies ( Table 1 ). The only mutation at Ser2035 that still retained FKBP12-rapamycin-binding activity is alanine. The aspartate and glutamate mutants, intended mimics of phosphoserine, showed no binding affinity. Thus, all residues larger than serine at this site abolished binding activity, apparently due to a steric effect or an induced conformational change. When the binding affinity of the S2035A mutant was compared with that of the wild-type protein (Fig. 5) , the mutant displayed an almost identical concentration dependence for FKBP12-rapamycin binding and had a comparable equilibrium dissociation constant (Table 1) . From these results, although we cannot demonstrate whether Ser2035 is a regulatory phosphorylation site, we can conclude that FKBP12-rapamycin binds FRAP with nonphosphorylated Ser2035. The W2027R mutation was also found to abrogate the binding of FRAP to FKBP12-rapamycin. This site resides in the minimal FRB domain, consistent with an involvement in FKBP12-rapamycin binding. In addition, conversion of Arg2036, which is part of the potential PKC site, to leucine did not alter the binding affinity.
Secondary Structure of the Minimal Binding Domain. For the purpose of structural studies, a 12-kDa FRB domain (aa 2015-2114) of FRAP was expressed and purified from E. coli cells by standard GST-fusion-protein isolation methods. The fusion protein was highly soluble when expressed at room temperature, indicating its proper folding in E. coli cells. The purified 12-kDa protein was indeed active; it displayed specific FKBP12-rapamycin binding affinity (Fig. 6B) . Since E. coli cells lack the eukaryotic machinery required for posttranslational modifications of mammalian proteins, the activity of this protein is again in concord with the model that phosphorylation of Ser2035 of FRAP is not required for binding to FKBP12-rapamycin. The CD spectrum of this FRB domain between 200 and 230 nm is characteristic of a polypeptide composed mainly of a-helix (25, 26) , which is consistent with a Chou-Fasman (software by Genetics Computer Group) which was then subcloned into pET-5a for subsequent in vitro transcription and translation. The binding assays were carried out as described in Materials and Methods. ND, not determined.
*Derived from the data in Fig. 3 . tDerived from the data in Fig. 4 On the basis of the rapamycin-resistant phenotype of yeast cells encoding an S1972R or S1972N mutation on their TOR1 gene (or S1975I on TOR2) (17, 19) , this serine residue has been speculated to play an important role in functional regulation. One possible mechanism is through serine phosphorylation, as it has been suggested to be a potential PKC site (19) . In vitro experiments have demonstrated the binding of TOR1 to FKBP12-rapamycin and the inability of S1972R mutant to bind FKBP12-rapamycin (X.-F.Z., unpublished work). Since this residue is also conserved in FRAP, we have used muta- 
